HanchorBio to Present Next-Generation Biologics Innovation at Biologics World Taiwan 2026
Company leaders to share perspectives on multispecific Fc-fusion therapeutics, AI-enabled development, and CMC strategy for emerging biologic modalities
HanchorBio will participate in Biologics World Taiwan 2026, to be held on March 25-26 at Hilton Taipei Sinban, Taiwan. At the event, Dr. Scott Liu, Founder, Chairman, and CEO, and Dr. Vivian Kuo, Executive Director, CMC, will join the speaker faculty to share perspectives on next-generation biologics innovation, spanning multispecific Fc-fusion therapeutics, translational development, and CMC strategy for emerging drug modalities.
Event Information
- Date: March 25–26, 2026
- Location: Hilton Taipei Sinban, Taiwan
HanchorBio’s participation reflects the company’s continued focus on advancing differentiated biologics designed to address complex disease biology through precision protein engineering, translational development, and disciplined execution across CMC and manufacturing. This effort is further supported by the company’s growing AI and Decision Science capabilities, which are being applied across structural biology, development strategy, and CMC decision-making.
Speaker Session(s)
March 25, 2026 | 11:25
Dr. Liu will present “Innovation in Immuno-Oncology through Development of Tri-specific Fc Fusion Proteins: From Discovery to IND Filing.”
His presentation will discuss the therapeutic rationale for multispecific Fc-fusion design, development considerations from discovery through IND-enabling stages, and the broader potential of these formats in next-generation immuno-oncology.
March 25, 2026 | 13:55
Dr. Kuo will present “From Complexity to Control: Process and CMC Excellence for the Next-Generation Innovative Drugs.”
Her session will focus on process and CMC challenges related to emerging biologic modalities, approaches for improving development control and manufacturability, and selected applications of AI-enabled modeling and decision support in development strategy. It will also highlight HanchorBio’s broader effort to incorporate AI and Decision Science into biologics development, including applications in structural biology and CMC optimization.
HanchorBio looks forward to engaging with industry peers, potential partners, and investors at the meeting, and to contributing to the broader discussion on how platform innovation can be translated into clinically meaningful therapeutic progress.
About Biologics World Taiwan 2026
Biologics World Taiwan is a prominent industry forum that brings together stakeholders involved in biologics research, development, manufacturing, and clinical translation. Held at a time when Taiwan is further advancing its biomedicine and biomanufacturing capabilities, the event offers a valuable platform for industry leaders, innovators, and investors to share perspectives on the future of biologics both across Asia and the global market.
About HanchorBio
Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (7827.TPEx) is a global clinical-stage biotechnology company focused on immuno-oncology and immune-mediated diseases. The company is led by an experienced team with a proven track record in biologics discovery and global development, aiming to reshape the landscape of cancer therapies. HanchorBio’s proprietary Fc-based designer biologics (FBDB™) platform enables the design of multi-functional biologics with diverse targeting modalities, designed to activate both innate and adaptive immune pathways and overcome the current challenges of anti-PD1/PD-L1 immunotherapies. The FBDB™ platform has delivered proof-of-concept data in several in vivo tumor animal models. HanchorBio is advancing a portfolio of innovative biologics designed to address significant unmet medical needs through differentiated molecular configurations in R&D and scalable CMC strategies.
漢康生技受邀於第13屆台灣世界生物製劑大會發表專題演講，分享次世代生物藥創新研發與CMC策略觀點
漢康生技將參與於2026年3月25日至26日在台北新板希爾頓酒店舉行之第13屆台灣世界生物製劑大會（Biologics World Taiwan 2026）。本次大會中，漢康生技創辦人、董事長暨執行長劉世高博士與CMC執行總監郭孟薇博士受邀擔任講者，分別就次世代融合蛋白藥物創新、臨床轉譯開發，以及新型態藥物之製程與CMC策略等主題，分享公司在生物藥研發與開發上的專業觀點與實務經驗。
漢康生技長期致力於開發具差異化優勢的創新生物藥，聚焦於複雜疾病生物機轉，並結合精準蛋白質工程、轉譯開發能力，以及CMC與製造執行經驗，推動次世代治療產品的臨床與產業化進程。近年公司亦持續建構AI與Decision Science能力，應用於結構生物學、開發策略與CMC決策支援，以提升研發效率與開發品質。
演講資訊：
2026年3月25日 上午11:25
劉世高博士（Scott Liu）
漢康生技創辦人、董事長暨執行長
講題：
Innovation in Immuno-Oncology through Development of Tri-specific Fc Fusion Proteins: From Discovery to IND Filing
本場演講將聚焦於三特異性Fc融合蛋白於腫瘤免疫治療的開發邏輯與臨床潛力，分享多功能融合蛋白平台從分子設計、候選藥物篩選，到IND申報前開發策略的整體思維，並探討此類新型態生物藥在次世代免疫腫瘤領域的應用前景。
2026年3月25日 下午1:55
郭孟薇博士（Vivian Kuo）
漢康生技CMC執行總監
講題：
From Complexity to Control: Process and CMC Excellence for the Next-Generation Innovative Drugs
本場演講將分享次世代新型態藥物在製程開發與CMC管理上所面臨的關鍵挑戰，並說明如何透過製程與分析策略強化開發可控性與製造品質，同時介紹AI模型與決策支援工具於開發策略中的應用案例。
會議資訊
會議名稱： 第13屆台灣世界生物製劑大會（Biologics World Taiwan 2026）
日期： 2026年3月25日至26日
地點： 台北新板希爾頓酒店（Hilton Taipei Sinban, Taiwan）
台灣世界生物製劑大會已邁入第13屆，為國內生物藥領域具代表性之年度產業會議之一，聚焦於生物藥研發、製造、CMC及臨床轉譯等關鍵議題，並持續促進國內外產業、技術與合作交流。
漢康生技表示，期望藉由參與本次大會，與產業夥伴、專家學者及投資界進一步交流，分享公司在次世代生物藥開發、融合蛋白平台設計，以及AI輔助開發策略上的經驗與觀點，持續推動能為病患帶來實質價值的創新療法。
2026台灣世界生物製劑大會：驅動台灣生醫創新，鏈結亞洲生技未來
在台灣持續推動生醫產業升級、加速發展生物製造能量之際，Biologics World Taiwan 2026 再度登場。作為台灣生物藥領域的重要年度盛會之一，本屆大會預計匯聚超過300位來自海內外的產業專家與企業代表，聚焦生物藥研發、製造、CMC、臨床試驗及新興技術應用等關鍵議題。
近年來，台灣持續強化對生醫產業的政策支持，涵蓋AI醫療研發、人才培育，以及生物製造基礎建設等面向。TBMC 的成立，以及疫情後各界對本土CDMO量能與供應鏈韌性的重視，也進一步凸顯台灣積極布局生物製造與生醫創新的戰略方向。
本屆大會將深入探討AI驅動研發、生物製造擴產、基因與細胞治療、製程優化、疫苗開發，以及台灣生技產業的全球化發展策略。隨著產業能量持續累積，台灣正穩步朝向更具國際競爭力的生醫創新與生物製造樞紐邁進。